A narrative review of immunotherapy for non-small cell lung cancer: current progress, sensitization approaches, and synergistic strategies.

ABSTRACT:

Background and objective

With increasing understanding of tumor immune tolerance mechanisms, a series of immune checkpoint molecules have been identified. Immune checkpoint blockade (ICB) therapy, which was developed based on these discoveries, has emerged as a promising strategy for the clinical treatment of non-small cell lung cancer (NSCLC), and has shown notable therapeutic benefits. However, the limited response rate remains a major barrier to further improving ICB efficacy and poses a significant challenge to the clinical management of NSCLC. This review summarizes recent advances in clinical immunotherapy for NSCLC and discusses future prospects in the field.

Methods

A systematic literature search was performed using the official websites of organizations and database

SUBMITTER: Zhou L 

PROVIDER: S-EPMC12432626 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature